Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Getting peptide vaccines to work: just a matter of quality control?
Esteban Celis
Esteban Celis
Published December 15, 2002
Citation Information: J Clin Invest. 2002;110(12):1765-1768. https://doi.org/10.1172/JCI17405.
View: Text | PDF
Commentary

Getting peptide vaccines to work: just a matter of quality control?

  • Text
  • PDF
Abstract

Commentary

Authors

Esteban Celis

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Formation of cryptic CTL epitopes by cleavage of amino-terminal residues...
Formation of cryptic CTL epitopes by cleavage of amino-terminal residues in a peptide vaccine. Peptides NY-ESO-1157-165 and NY-ESO-1157-167, representing HLA-A2–restricted CTL epitopes, were used to vaccinate cancer patients. By the action of an aminopeptidase (P), peptide NY-ESO-1157-167 can generate the truncated peptides NY-ESO-1158-167 and NY-ESO-1159-167, which are also capable of binding to HLA-A2 molecules and were shown to induce low-quality CTLs that failed to recognize tumor cells. Anchor residues, within the peptides, that facilitate MHC binding are shown in boldface. In the case of NY-ESO-1157-165, the cysteine (C) anchor is likely to be suboptimal, since it does not represent a canonical HLA-A2–binding motif.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts